ReviewImmunologic research2010
Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence.
Review in Immunologic research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review.Medicine · 2020Pooled it
- A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs.The Journal of infectious diseases · 2011Pooled it
- A randomized trial of a hepatitis care coordination model in methadone maintenance treatment.American journal of public health · 2013Trial
- Trial
- Contemporary Insights into Hepatitis C Virus: A Comprehensive Review.Microorganisms · 2024Review
- A short hepatitis C virus NS5A peptide expression by AAV vector modulates human T cell activation and reduces vector immunogenicity.Gene therapy · 2022Article
- Sero-reactivity to three distinct regions within the hepatitis C virus alternative reading frame protein (ARFP/core+1) in patients with chronic HCV genotype-3 infection.The Journal of general virology · 2022Article
- CD8Frontiers in immunology · 2022Article
- Reversal of T Cell Exhaustion in Chronic HCV Infection.Viruses · 2020Review
- Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- High prevalence of occult hepatitis C infection in predialysis patients.World journal of hepatology · 2019Article
- Aminoacyl-tRNA synthetases, therapeutic targets for infectious diseases.Biochemical pharmacology · 2018Review
- Next-generation sequencing analysis of a cluster of hepatitis C virus infections in a haematology and oncology center.PloS one · 2018Article
- Autoantigens as Partners in Initiation and Propagation of Autoimmune Rheumatic Diseases.Annual review of immunology · 2016Review
- PD-1/PD-L1 signal pathway participates in HCV F protein-induced T cell dysfunction in chronic HCV infection.Immunologic research · 2016Article
- Article
- Human Pegivirus (HPgV; formerly known as GBV-C) inhibits IL-12 dependent natural killer cell function.Virology · 2015Article
- Tropism of human pegivirus (formerly known as GB virus C/hepatitis G virus) and host immunomodulation: insights into a highly successful viral infection.The Journal of general virology · 2015Review
- Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women.Journal of acquired immune deficiency syndromes (1999) · 2014Article
- Hepatitis C virus infection in the human immunodeficiency virus infected patient.World journal of gastroenterology · 2014Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Hepatitis C virus (HCV) infects over 170 million people worldwide and is a leading cause of cirrhosis and hepatocellular carcinoma. Approximately 20% [corrected] of those acutely infected clear the infection, whereas the remaining 80% [corrected] progress to chronic infection. Hepatitis C thus provides a model in which successful and unsuccessful responses can be compared to better understand the human response to viral infection. Our laboratory studies the strategies by which HCV evades the adaptive immune response. This review describes the impact of viral mutation on T cell recognition, the role of cell surface inhibitory receptors in recognition of HCV, and the development of antibodies that neutralize HCV infection. Understanding what constitutes an effective immune response in the control of HCV may enable the development of prophylactic and therapeutic vaccines for HCV and other chronic viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.